| 000 | 01794 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518021313.0 | ||
| 264 | 0 | _c20190923 | |
| 008 | 201909s 0 0 eng d | ||
| 022 | _a1932-6203 | ||
| 024 | 7 |
_a10.1371/journal.pone.0209911 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBernardino, Jose I | |
| 245 | 0 | 0 |
_aBody composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial. _h[electronic resource] |
| 260 |
_bPloS one _c2019 |
||
| 300 |
_ae0209911 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdipokines _xblood |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aBody Composition |
| 650 | 0 | 4 | _aBody Mass Index |
| 650 | 0 | 4 |
_aEmtricitabine, Tenofovir Disoproxil Fumarate Drug Combination _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFibroblast Growth Factor-23 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aRaltegravir Potassium _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aMocroft, Amanda | |
| 700 | 1 | _aWallet, Cedrick | |
| 700 | 1 | _ade Wit, Stéphane | |
| 700 | 1 | _aKatlama, Christine | |
| 700 | 1 | _aReiss, Peter | |
| 700 | 1 | _aMallon, Patrick W | |
| 700 | 1 | _aRichert, Laura | |
| 700 | 1 | _aMolina, Jean-Michel | |
| 700 | 1 | _aKnobel, Hernando | |
| 700 | 1 | _aMorlat, Philippe | |
| 700 | 1 | _aBabiker, Abdel | |
| 700 | 1 | _aPozniac, Anton | |
| 700 | 1 | _aRaffi, Francois | |
| 700 | 1 | _aArribas, Jose R | |
| 773 | 0 |
_tPloS one _gvol. 14 _gno. 1 _gp. e0209911 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1371/journal.pone.0209911 _zAvailable from publisher's website |
| 999 |
_c29299899 _d29299899 |
||